113 results on '"Solans-Laqué R"'
Search Results
2. POS1247 CHARACTERIZATION OF 284 PATIENTS PRESENTING WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OF SJÖGREN DISEASE: RESULTS FROM THE SJÖGREN BIG DATA REGISTRY
3. OP0082 GENE EXPRESSION PROFILE OF CD4+ T LYMPHOCYTES IS MODIFIED IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
4. POS1424 TOCILIZUMAB IN EXTRACRANIAL LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: COMPARATIVE MULTICENTER STUDY
5. POS1100 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL SUSPICION RED FLAGS IDENTIFICATION BY A SYSTEMATIC LITERATURE REVIEW AND MULTIDISCIPLINARY EXPERT CONSENSUS
6. AB1320 DOPPLER ULTRASOUND IN GIANT CELL ARTERITIS: WHICH TERRITORIES SHOULD WE EXPLORE? A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE
7. POS1246 CHARACTERIZATION OF 785 PATIENTS WITH PULMONARY MANIFESTATIONS OF SJÖGREN DISEASE: RESULTS FROM THE BIG DATA SJÖGREN REGISTRY
8. AB0821 RAYNAUD’S PHENOMENON IDENTIFIES A SUBSET OF PATIENTS WITH SJOGREN SYNDROME, INTERSTITIAL LUNG FIBROSIS, AND GREATER DISEASE ACTIVITY
9. OP0102 IDENTIFICATION OF NEW RISK LOCI AND PATHWAYS INVOLVED IN GCA PATHOGENESIS BY A GENOME-WIDE STUDY
10. POS1175 ANTI-IL5 THERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: DOSAGE, EFFICACY AND OUTCOME IN A LARGE COHORT OF PATIENTS IN REAL LIFE (REVAS STUDY)
11. POS0246 SEQUENTIAL RITUXIMAB AND MEPOLIZUMAB IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
12. POS0804 TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
13. AB0464 ULTRASONOGRAPHIC FEATURES OF THE PAROTID AND SUBMANDIBULAR SALIVARY GLANDS IN SJÖGREN’S SYNDROME
14. POS0732 CLINICAL, HISTOLOGICAL, AND SEROLOGICAL FEATURES ASSOCIATED WITH SALIVARY GLAND ULTRASOUND IN PRIMARY SJÖGREN’S SYNDROME
15. AB0468 COMPARISON OF THE DIAGNOSTIC PERFORMANCE OF SALIVARY GLAND SCINTIGRAPHY AND ULTRASOUND IN SJÖGREN’S SYNDROME
16. POS0271 CLINICAL SYMPTOMS AT GIANT CELL ARTERITIS DIAGNOSIS AS PREDICTORS OF PERMANENT VISUAL LOSS.
17. AB0566 CLINICAL AND SEROLOGICAL ASSOCIATION BETWEEN SJÖGREN SYNDROME AND VASCULITIS
18. AB0467 COMPARISON OF 2002 AECG AND 2016 ACR/EULAR CLASSIFICATION CRITERIA AND ROLE OF SALIVARY GLAND ULTRASONOGRAPHY IN A SICCA COHORT
19. AB0366 TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
20. 135 - Vasculitis
21. Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry)
22. OP0033 OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 134 PATIENTS
23. THU0297 SERIOUS INFECTIONS IN 134 PATIENTS WITH GIANT CELL ARTERITIS WITH TOCILIZUMAB IN CLINICAL PRACTICE. FREQUENCY, TYPE AND CLINICAL ASSOCIATIONS
24. SAT0270 TOCILIZUMAB IN REFRACTORY TAKAYASU ARTERITIS. OPEN-LABEL NATIONAL MULTICENTER STUDY OF 53 PATIENTS OF CLINICAL PRACTICE
25. How the age at diagnosis modifies the phenotype of primary Sjögren syndrome: analysis in 11.420 patients (Big data Sjögren project
26. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity
27. Fetal microchimerism in Sjögrenʼs syndrome
28. Capítulo 128 - Vasculitis
29. OP0051 Evolution of the vascular involvement objectified by pet/tac in patients with giant cell arteritis treated with tocilizumab
30. THU0449 Diagnostic performance of antineutrophil cytoplasmic antibodies in a cohort of unselected spanish patients
31. FRI0500 Extracranial vascular affection in giant cell arteritis
32. IDENTIFICATION OF NEW RISK LOCI AND PATHWAYS INVOLVED IN GCA PATHOGENESIS BY A GENOME-WIDE STUDY.
33. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity
34. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and Patient indexes (ESSPRI)
35. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). in combination wiIh methotrexate
36. AB0549 Anca Testing in A Cohort of Patients from A Single Centre
37. THU0570 Use of Disease-Modifying anti-Rheumatic Drugs in A Cohort of Patients with IGG4-Related Disease
38. IgG4-Related Disease: Results From a Multicenter Spanish Registry
39. Sequence analysis ofTMEM173exon 5 in patients with systemic autoimmune diseases
40. ANTI-IL5 THERAPY IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: DOSAGE, EFFICACY AND OUTCOME IN A LARGE COHORT OF PATIENTS IN REAL LIFE (REVAS STUDY).
41. FRI0275 Long-Term Survival and Baseline Prognostic Factors in a Wide Series of Patients with AAV from Spain. Usefulness of Prognostic Scores (Revas Study)
42. Prevalence of HHV-8 in systemic autoimmune diseases
43. SAT0288 Eosinophilic Granulomatosis with Poliangeitis (EGPA): Clinical Features and Outcome in A Large Serie of Spanish Patients
44. AB0548 Interstitial Lung Disease (ILD) in Primary SjÖGren Syndrome: Clinical, Immunological and Radiological Features and Outcome
45. SAT0174 Clinical and Histological Features in Patients with Permanent Visual Los Due to Biopsy-Proven Giant Cell Arteritis
46. AB0049 Eotaxin is overexpressed in churg-strauss syndrome compared to allergic asthma
47. THU0226 Clinical features and mortality causes in a large cohort of spanish patients with anca associated vasculitides
48. FRI0303 Validation of eular primary sjögren’s syndrome disease activity and patient indexes
49. AB0449 Isolated aortitis as an atypical presentation of giant cell arteritis
50. AB0707 Arthritis prevalence and biological markers in primary sjÖgren’s syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.